Andreas Schaaf

Title: Innovations by Andreas Schaaf in Glycosylated Lysosomal Proteins

Introduction

Andreas Schaaf is an accomplished inventor based in Freiburg, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of glycosylated lysosomal proteins. With a total of 3 patents, his work focuses on improving therapeutic efficacy for various diseases.

Latest Patents

One of his latest patents is titled "Glycosylated lysosomal proteins, method of production and uses." This invention relates to a lysosomal protein composition that includes a variety of lysosomal proteins, which are potentially diversely glycosylated according to a specific glycosylation pattern. Notably, this pattern contains at least 45% paucimannosidic N-glycans. The patent also describes a method for manufacturing this lysosomal protein composition in a bryophyte plant or cell, along with its medical and non-medical applications. For instance, the lysosomal protein can be α-Galactosidase for treating Fabry Disease or β-Glucoceramidase for Gaucher's Disease. The unique glycosylation achieved through this method results in improved therapeutic efficacy, surprisingly even without the mannose-6-phosphate that is typically found in CHO cell-produced lysosomal proteins.

Career Highlights

Throughout his career, Andreas has worked with notable companies such as Eleva GmbH and Greenovation Biotech GmbH. His expertise in the field has allowed him to contribute to advancements in biopharmaceuticals and therapeutic proteins.

Collaborations

Andreas has collaborated with several professionals in his field, including Paulina Dabrowska-Schlepp and Fode Benjamin. These collaborations have further enriched his research and development efforts.

Conclusion

Andreas Schaaf's innovative work in glycosylated lysosomal proteins showcases his commitment to advancing medical science. His patents reflect a deep understanding of biochemistry and a dedication to improving therapeutic outcomes for patients.